TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03301454

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pursuit of chemotherapy
Description: Treatment with LV5FU2 (5-FU, Calcium Levofolinate) - paclitaxel, regular tumor evaluation, best supportive care Other authorized treatment : usual paclitaxel pre-treatment consisting of Dexamethasone, Chlorpheniramine and ranitidine, at 15 and 1 day before the actual paclitaxel treatment
Study: NCT00924534

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLV337
Description: SLV337 400 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLV337
Description: SLV337 800 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLV337
Description: SLV337 1400 mg/day
Study: NCT00303836

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic autologous lymphocytes
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic autologous lymphocytes
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: in vitro-treated peripheral blood stem cell transplantation
Description: Undergo in vitro-treated peripheral blood stem cell transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: in vitro-treated peripheral blood stem cell transplantation
Description: Undergo in vitro-treated peripheral blood stem cell transplantation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gp100 antigen
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gp100 antigen
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MART-1 antigen
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MART-1 antigen
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: incomplete Freund's adjuvant
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: incomplete Freund's adjuvant
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aldesleukin
Description: Given IV
Study: NCT02770430

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mesenchymal stem cells
Description: MSCs derived from bone marrow (BM) will be isolated and expanded in the laboratory under conditions of Good Manufacturing Practice. The quality control involves immunophenotyping, differentiation, microbiological control, mycoplasma and endotoxin tests. Patients will receive five infusions of MSC. Dosage: 2x10E6 cells/Kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: conventional treatment
Description: 1. Basiliximab 20mg dose for adults and 10mg for children, 1 time a week or every 3 days if worsens the stage of GVHD until reaching Very Good Partial Response (VGPR) or for a maximum of 4 doses, whichever comes first.~2. If after the item (1) will not obtained VGPR: Infliximab 5 to 10 mg/kg dose, 1 time a week, four weeks or even VGPR.
Study: NCT01712113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irbesartan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avapro
Study: NCT00476060

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous mesenchymal stem cell transplantation
Description: Arm A: 300 million cells will be infused one time through a peripheral vein/// Arm B: Infusion of placebo one time through a peripheral vein

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Autologous mesenchymal stem cell transplantation
Description: Arm A: 300 million cells will be infused one time through a peripheral vein/// Arm B: Infusion of placebo one time through a peripheral vein
Study: NCT03795558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etelcalcetide
Description: Up-Titration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etelcalcetide
Description: Up-Titration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etelcalcetide
Description: Up-Titration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etelcalcetide
Description: Up-Titration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etelcalcetide
Description: Up-Titration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etelcalcetide
Description: Up-Titration
Study: NCT03008915

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: 81mg aspirin taken once per day in the morning

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aspirin
Description: 81mg aspirin taken once per day in the morning

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: placebo taken once per day in the morning

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo taken once per day in the morning

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Withdrawal from alpha1 antitrypsin replacement therapy
Description: After the completion of the randomization to aspirin and placebo, participants who are on alpha1 replacement therapy are asked to withhold their usual alpha1 antitrypsin replacement therapy for 5 weeks. This is not randomized.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Withdrawal from alpha1 antitrypsin replacement therapy
Description: After the completion of the randomization to aspirin and placebo, participants who are on alpha1 replacement therapy are asked to withhold their usual alpha1 antitrypsin replacement therapy for 5 weeks. This is not randomized.
Study: NCT01376336

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Safe storage device
Description: This device is a specially designed water storage container that is intended to reduce the likelihood of re-contamination of household stored drinking water.
Study: NCT00794118

Intervention type: OTHER
Intervention: As per clinical practice
Description: As per clinical practice
Study: NCT00174707

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epidoxorubicine, ciclophosphamide, methotrexate, fluorouracile
Description: Sequential Epidoxorubicin followed by ciclophosphamide/Methotrexate/fluorouracile (±TAM)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epidoxorubicine, docetaxel, ciclophosphamide, methotrexate, fluorouracile
Description: Sequential Epidoxorubicin followed by Docetaxel followed by ciclophosphamide/methotrexate/fluorouracile (± TAM)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epidoxorubicine, docetaxel, cyclophosphamide
Description: Sequential Intensified Epidoxorubicin followed by Docetaxel followed by Cyclophosphamide (± TAM)
Study: NCT02128620

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Game-Based Appointment System
Description: Users randomized to the www.sjekkdeg.no B version, consisting in the web app www.sjekkdeg.no including the Game-Based Appointment System
Study: NCT01240811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IUD placement
Description: Volunteer subjects who are not at risk of pregnancy because they are either surgically sterilized or heterosexually abstinent will be enrolled into the control group (no intervention). All other volunteers will be seeking an IUD for contraception and will be randomized to LNG-IUD (Mirena) or Copper IUD (ParaGard).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IUD placement
Description: Volunteer subjects who are not at risk of pregnancy because they are either surgically sterilized or heterosexually abstinent will be enrolled into the control group (no intervention). All other volunteers will be seeking an IUD for contraception and will be randomized to LNG-IUD (Mirena) or Copper IUD (ParaGard).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levonorgestrel IUD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copper T380A IUD
Study: NCT03108144

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief alcohol intervention
Description: The intervention is a clinical decision support system (CDSS) that provides a computerized prompt in the clinic's online portal. The CDSS prompts a practitioner to intervene when a patient is screening above recommended drinking guidelines. The prompt appears as an alert message, recommending intervention. The portal suggests scripted brief intervention language, designed based on the College of Family Physicians of Canada and Canadian Centre on Substance Abuse's resource on conducting evidence-based Screening, Brief Intervention, and Referral to Treatment (SBIRT) guidelines.
Study: NCT01554540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cutaneous iontophoresis of treprostinil
Description: Cutaneous iontophoresis of treprostinil 0.1mg/ml, on the forearm and the fingers. (charge 40-240 mC).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cutaneous iontophoresis of treprostinil
Description: Cutaneous iontophoresis of treprostinil 0.1mg/ml, on the forearm and the fingers. (charge 40-240 mC).
Study: NCT04243135

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ESWT
Description: Extracorporeal shock wave therapy

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: ESWT
Description: Extracorporeal shock wave therapy
Study: NCT02478541

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sugar study
Description: Subjects are given a single test meal on two study days that has a sugary drink that varies in the amount of fructose and glucose it contains. They consume the same amount of fat on both study days.
Study: NCT00882726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO 3649 IV (Healthy participants)
Description: Healthy participants will each receive a single dose of CNTO 3649 (1, 3, 10, 30, 100 or 300 microgram per kilogram, subject to change) as a 2-hour IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO 3649 SC (Healthy participants)
Description: Healthy participants will each receive a single dose of CNTO 3649 (10, 30, 100 or 300 microgram per kilogram, subject to change) as a SC injection.
Study: NCT04057248

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dario Blood Glucose Monitoring System
Description: Dario Blood Glucose Monitoring System (BGMS) with Dario App and Dario digital platform

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CDE
Description: Certified Diabetes Educator Sessions
Study: NCT00922324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STP206 or vehicle control
Description: STP206 or vehicle administered as either a single dose or as a daily dose for 7 consecutive days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: STP206 or vehicle control
Description: STP206 or vehicle administered as either a single dose or as a daily dose for 7 consecutive days
Study: NCT00882726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO 3649 SC (Diabetic patients)
Description: Diabetic patients will receive multiple doses of CNTO 3649 (30, 100 or 300 microgram per kilogram, subject to change) as subcutaneous injections once weekly for 4 consecutive weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants within each dosing group who are randomized to placebo will receive a corresponding IV infusion or SC injection of placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants within each dosing group who are randomized to placebo will receive a corresponding IV infusion or SC injection of placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants within each dosing group who are randomized to placebo will receive a corresponding IV infusion or SC injection of placebo.
Study: NCT04068467

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smartphone App
Description: The application consists of content areas focused on mental health.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Waitlist Control
Description: Waitlist control
Study: NCT00300300

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computer-assisted surgery
Description: no description
Study: NCT01263210

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevenar
Study: NCT00171340

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Description: Zolendronic acid 4 mg Intravenous (IV) 15 minute infusion every 6 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Description: Zolendronic acid 4 mg Intravenous (IV) 15 minute infusion every 6 months.
Study: NCT03514134

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality Job Interview Training
Description: Students will engage in didactic training related to strategies to perform well during a job interview as well as repeated practice with a virtual hiring manager. Throughout and after completion of the virtual interviews, participants will receive feedback on their performance.
Study: NCT00922675

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Postconditioning
Description: After opening of IRA and establishment of TIMI-flow grade 2 or 3, the control group continues the procedure with stenting. In the postconditioning group 4 additional balloon inflations separated by 1 minute reperfusion are given, starting after 1 minute of reperfusion.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Control intervention
Description: After opening of IRA and establishment of TIMI-flow grade 2 or 3, the control group continues the procedure with stenting.
Study: NCT05076656

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus fermentum D3
Description: Lactobacillus fermentum D3 in a white, gelatin capsule (orally), with lyophilized L. fermentum D3 without preservatives, sugars, or additives.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplant (FMT)
Description: Fecal microbiota transplant (FMT) in a green, gelatin capsule (orally), with lyophilized fecal material.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo in a white, gelatin capsule (orally), with powder milk
Study: NCT02207075

Intervention type: DRUG
Intervention: [C11]PK-1195 PET scan
Description: PET scan with tracer \[C11\]PK-1195

Intervention type: DRUG
Intervention: [C11]PK-1195 PET scan
Description: PET scan with tracer \[C11\]PK-1195
Study: NCT00187239

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Autointrinsic Conduction Search Algorithm
Description: Autointrinsic conduction search is programmed on in those patients randomized to AICS ON.
Study: NCT02196038

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: multi-domain rehabilitation intervention
Description: Individual, tailored, progressive physical function rehabilitation intervention

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Attention Control
Description: Usual care with bi-weekly contact from study staff
Study: NCT01913249

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LIFT
Description: Ligation of intersphincteric fistula tract

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LIFT
Description: Ligation of intersphincteric fistula tract
Study: NCT03226080

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium
Description: The neuromuscular blockade group will receive intravenous rocuronium

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex
Description: The neuromuscular blockade group will receive intravenous sugammadex for reversal of residual rocuronium

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline will be administered as a placebo in equal volume for the placebo group
Study: NCT00516269

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: 18 mg by mouth daily for 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: 18 mg by mouth daily for 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Capsule by mouth daily for 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Capsule by mouth daily for 2 weeks
Study: NCT01468909

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib Hydrochloride
Description: Given PO

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given PO
Study: NCT02592629

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine
Description: used with Kenalog in shoulder injection and as topical anesthetic as subcutaneous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine
Description: used with Kenalog in shoulder injection and as topical anesthetic as subcutaneous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine
Description: used with Kenalog in shoulder injection and as topical anesthetic as subcutaneous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ethyl chloride
Description: topical spray

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Kenalog
Description: used with lidocaine in shoulder injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Kenalog
Description: used with lidocaine in shoulder injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Kenalog
Description: used with lidocaine in shoulder injection
Study: NCT02076256

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The helping relationships intervention program
Study: NCT00256048

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nasojejunal feeding
Study: NCT00066625

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT00171340

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole tablets 2.5 mg/day taken orally for 5 years.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole tablets 2.5 mg/day taken orally for 5 years.
Study: NCT03570281

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edoxaban
Description: Edoxaban, per oral, 60mg qd (may consider reduced dose to 30mg qd in patients with proper clinical reason by attending physician, estimated creatinine clearance of 30 to 50 ml per minute, a body weight of 60 kg or less, or the concomitant use of verapamil or quinidine), for 90 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: Enoxaparin, subcutaneous injection, 1mg/kg BID (may consider reduced dose to 1mg/kg qd in patients with proper clinical reason by attending physician, Creatinine clearance \<30 mL/min), for 90 days.
Study: NCT02668107

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hammock positioning
Description: Babies in the intervention group (IG), will be positioned supine in a hammock(hammock positioning) in the incubator, with the appropriate postural adjustments.
Study: NCT01597128

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Flex HD
Description: Flex HD mesh for hernia repair
Study: NCT02771041

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: medical consultation 8 days before surgery
Description: This consultation would serve to explain to the patient the early course of care, give advice and help to anticipate acts for its release post-operative as, for example, contact a physical therapist and a nurse or check to their community pharmacy if their heparin stock is enough and to answer any questions.
Study: NCT03172052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: streptokinase
Description: • Chemical adhesiolysis by instillation of streptokinase at a dose of 250,000 I.U dissolved in 40 ml of normal saline will be instil in the pleural cavity through the chest tube. we planning to continue the daily instillation as long as the drained fluid volume is \>100 cc with a maximum of 14 doses and to stop further instillation if severe complication occurred.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: streptokinase
Description: • Chemical adhesiolysis by instillation of streptokinase at a dose of 250,000 I.U dissolved in 40 ml of normal saline will be instil in the pleural cavity through the chest tube. we planning to continue the daily instillation as long as the drained fluid volume is \>100 cc with a maximum of 14 doses and to stop further instillation if severe complication occurred.
Study: NCT01597128

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Strattice
Description: Strattice mesh for hernia repair
Study: NCT00667745

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium Carbonate
Description: Lithium was started at 300 mg and then increased to 600 mg after 3 days. Lithium doses were maintained at 600 mg per day for 8 weeks, but may have been adjusted after that time as needed up to a serum level of 1.2 mEq/L.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optimized Treatment (OPT)
Description: The foundation of OPT was to maintain treatment that will typically include at least one FDA-approved mood stabilizer other than lithium (e.g., divalproex, carbamazepine, risperidone, quetiapine, olanzapine, aripiprazole, ziprasidone) and to follow the recommendations summarized in the evidence-based stages of the Texas Implementation of Medication Algorithm (TIMA) revised guidelines.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Optimized Treatment (OPT)
Description: The foundation of OPT was to maintain treatment that will typically include at least one FDA-approved mood stabilizer other than lithium (e.g., divalproex, carbamazepine, risperidone, quetiapine, olanzapine, aripiprazole, ziprasidone) and to follow the recommendations summarized in the evidence-based stages of the Texas Implementation of Medication Algorithm (TIMA) revised guidelines.